CDC: Increases in NDM-CRE in the United States

 

New CDC Report Warns of Increases in NDM-CRE, Urges Healthcare Provider Awareness and Testing

Through CDC’s Antimicrobial Resistance Laboratory Network, CDC experts have detected a substantial rise in carbapenem-resistant Enterobacterales (CRE) producing the New Delhi metallo-β-lactamase (NDM) carbapenemase. This increase in NDM-CRE has also been observed in complementary CDC surveillance platforms.  These increases in carbapenemase-producing-CRE (CP-CRE) and NDM-CRE threaten to reverse years of stable or declining CRE rates and are particularly concerning due to the limited treatment options for CRE infections involving these resistance mechanisms.

A CDC paper recently published in the Annals of Internal Medicine describes the changes in carbapenemase genes in CRE isolates from 2019 to 2023. Findings include: In a cohort of 29 U.S. states with mandated submission of CRE isolates, the incidence of CP-CRE isolates from clinical cultures increased dramatically overall between 2019 and 2023.  The increased incidence was primarily driven by a five-fold increase in the incidence of NDM-CRE and a smaller increase in OXA-48-like-CRE.  Preliminary data from 2024 indicate NDM-CRE remained at or above 2023 levels. To increase timely detection, guide treatment, and prevent the spread of CRE, healthcare providers should: Understand if their clinical laboratories have the testing capabilities to identify different carbapenemase genes or access testing through their public health laboratory. Consult with their Healthcare-associated Infections and Antimicrobial Resistance (HAI/AR) Program to understand local CRE resistance mechanisms in their area.  Implement infection prevention and control measures effective in preventing CRE.  Read the report to learn more about these alarming increases in the United States and actions to prevent the spread of CRE: http://bit.ly/4nKi2Vo.

	@CDCgov finds alarming increase of New Delhi metallo-β-lactamase producing carbapenem-resistant Enterobacterales (NDM-CRE) in lab testing & surveillance. This reverses previous declines in CRE. Read research: http://bit.ly/4nKi2Vo.

U.S. Centers for Disease Control and Prevention 1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348